Compounds are provided having the following structure: Formula (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R.sup.1, R.sup.2, G.sup.1, G.sup.2 and n are as defined herein. Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups.

The present disclosure is drawn to an amine synergist including a tertiary benzylamine with a substituted benzene ring attached to a tertiary amine. The tertiary amine can be modified with multiple water soluble groups.

The present invention specifically relates to novel salt and crystalline form of haloacetic acid and its process of preparation. The invention more particularly relates to novel crystalline form dichloroacetate tromethamine salt and its process of preparation. The present invention more specifically relates to the dichloroacetate tromethamine salt, its process and its use for the treatment of various diseases and/or disorders.

The present invention specifically relates to novel salt and crystalline form of haloacetic acid and its process of preparation. The invention more particularly relates to novel crystalline form dichloroacetate tromethamine salt and its process of preparation. The present invention more specifically relates to the dichloroacetate tromethamine salt, its process and its use for the treatment of various diseases and/or disorders.

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.

##STR00001##

The present invention relates to a compound which is (R)-3-(1,4-dimethyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-(3-(((R)-2-ethyl-2,3-dihydropyrido[2,3-f][1,4]oxazepin-4(5H)-yl)methyl)-4-methylphenyl)propanoic acid (I), or a pharmaceutically acceptable salt thereof, in particular, the meglumine salt thereof, a pharmaceutical composition containing the compound and its use as an NRF2 activator.

##STR00001##

Provided are a novel compound and a hydrogen-bonding material treatment agent that are useful for treating various hydrogen-bonding materials such as biological samples. They are an organic ammonium salt and a hydrogen-bonding material treatment agent containing the same. The organic ammonium salt is solid at 25 C., and contains an anion and an ammonium cation represented by the following formula (I):

N.sup.R.sub.nH.sub.4-n(I)

wherein R independently represents, for example, a hydroxyalkyl group in which there is at least one hydroxy group, an alkyl moiety is a linear or branched moiety having 1 to 10 carbon atoms, and the alkyl moiety may contain an oxygen atom(s), and n represents an integer of 0 to 4.

The invention relates to compounds of formula (I):

##STR00001## wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.

The invention relates to compounds of formula (I):

##STR00001## wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.